FDA Approved: ABIRATERONE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for ABIRATERONE ACETATE (BluePoint Laboratories) under ANDA 210686.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)

Snippet

SUPPL AP for ABIRATERONE (ABIRATERONE ACETATE)